ERBB2 and breast cancer: Another ADAM17 inhibitor, INCB7839, was used to present HER2 cleavage and to treat patients with HER2-positive breast cancer in combination with trastuzumab and it is also in clinical trials to prevent CD20 cleavage in combination with rituximab for the treatment of diffuse large B-cell NHL (268).